Antitumor photosensitizer-10

Antitumor photosensitizer-10 是一种抗肿瘤光敏剂,在近红外照射下可产生超氧阴离子,降低谷胱甘肽的铜结合能力并释放铜离子,进而诱导肿瘤细胞发生铜死亡 (cuproptosis),可用于乳腺癌相关研究。
Antitumor photosensitizer-10
产品编号: MS-P62822 分子式: C36H37Cl2CuN5O2S2+ 分子量: 738.23
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Antitumor photosensitizer-10 是一种抗肿瘤光敏剂,在近红外照射下可产生超氧阴离子,降低谷胱甘肽的铜结合能力并释放铜离子,进而诱导肿瘤细胞发生铜死亡 (cuproptosis),可用于乳腺癌相关研究。

生物实验数据

生物活性 Antitumor photosensitizer-10 is an antitumor photosensitizer that, upon near-infrared irradiation, generates superoxide anions, reduces the copper-binding capacity of glutathione, and releases copper ions, thereby inducing cuproptosis in tumor cells, and can be used for breast cancer-related research.
体外研究
(In Vitro)

Antitumor photosensitizer-10 (Compound NC) (10 μM; 1-7 min) 经 660 nm 光照后,可在无细胞 PBS 体系中产生大量超氧阴离子自由基。
Antitumor photosensitizer-10 (1 μM; 4-16 h) 可有效将铜离子递送至 4T1 细胞,孵育 4 h 和 16 h 后细胞内铜水平呈时间依赖性升高。
Antitumor photosensitizer-10 (0.125-2 μM) 在 660 nm 光照下对 4T1 细胞表现出增强的光毒性,在 6 J cm-2 条件下的 IC50 为 216 nM。
Antitumor photosensitizer-10 (250 nM; 24 h) 处理后再进行 660 nm 辐照,可诱导 4T1 细胞发生显著死亡;与暗对照组和 NQ 处理组相比,该处理的 PI 染色增强、calcein-AM 染色减弱,证明了这一结果。
Antitumor photosensitizer-10 (250 nM; 12 h) 经 660 nm 照射后可在 4T1 细胞中产生细胞内活性氧 (ROS)。
Antitumor photosensitizer-10 (250 nM; 24 h) 在 660 nm 辐照下可诱导 HCT116 和 4T1 细胞发生铜死亡相关变化,包括 FDX1 表达降低和 DLAT 聚集增加。
Antitumor photosensitizer-10 (250 nM; 24 h) 仅在 660 nm 辐照条件下可诱导 4T1 细胞发生 DLAT 聚集 (铜死亡的标志性事件),该结果经免疫荧光成像证实。
Antitumor photosensitizer-10 (0.25-2 μM; 36 h) 在高浓度黑暗条件下经 BSO 预处理后,其在 4T1 细胞中诱导的铜死亡被增敏;经 660 nm 照射后,其光毒性被协同增强,这证实谷胱甘肽 (GSH) 耗竭介导了光动力疗法 (PDT) 与铜死亡之间的协同作用。
Antitumor photosensitizer-10 (250 nM; 12 h) 在 660 nm 照射下会产生活性氧 (ROS),该活性氧可介导 4T1 细胞内谷胱甘肽 (GSH) 耗竭及后续的 DLAT 聚集;而经 BSO 预处理后与低剂量光照联用,可协同诱导与铜死亡相关的 DLAT 聚集。

Western Blot Analysis

Cell Line: HCT116 human colon cancer cells, 4T1 mouse breast cancer cells
Concentration: 250 nM
Incubation Time: 12 h (treatment); 200 s (irradiation at 20 mW cm-2); 12 h (post-treatment incubation)
Result: Reduced FDX1 expression markedly in HCT116 cells under light, similar to the positive control (elesclomol + CuCl2).
Induced DLAT aggregation (oligomer formation) in 4T1 cells under light, with more aggregation bands than the positive control (8-HQ-COOH + CuCl2).
Did not alter FDX1 or DLAT levels in the dark compared to controls.

Immunofluorescence

Cell Line: 4T1 mouse breast cancer cells
Concentration: 250 nM
Incubation Time: 12 h (treatment); 200 s (irradiation at 20 mW cm-2); 12 h (post-treatment incubation)
Result: Induced DLAT foci (indicative of aggregation) only in the NC + light group, similar to the positive control (elesclomol + CuCl2).
Showed DLAT fluorescence patterns identical to the control group (no visible aggregation foci) in NC dark, NQ dark, and NQ light conditions.

Cell Viability Assay

Cell Line: 4T1 mouse breast cancer cells
Concentration: 0.25-2 μM (NC); 20 μM (BSO)
Incubation Time: 12 h (BSO preincubation); 12 h (NC treatment); 200 s (irradiation at 20 mW cm-2); 12 h (post-treatment incubation)
Result: Showed no effect on NC's dark cytotoxicity at low concentrations with BSO pre-treatment, but reduced cell survival at higher concentrations, indicating sensitization to cuproptosis.
Enhanced NC's phototoxicity beyond additive effects of BSO and PDT alone under light irradiation, with greater reduction in cell survival than BSO + NQ light groups at low concentrations.

Immunofluorescence

Cell Line: 4T1 mouse breast cancer cells
Concentration: 250 nM (NC); 20 μM (BSO); 1 mM (Vc)
Incubation Time: 12 h (BSO preincubation); 5 min (Vc pre-irradiation treatment); 90-200 s (irradiation at 20 mW cm-2)
Result: Induced marked DLAT foci in NC-treated cells when combined with BSO pre-treatment and low-dose light, while neither BSO alone nor low-dose light alone induced aggregation.
Induced DLAT foci in NC-treated cells with high-dose light alone, and addition of Vc markedly reduced these foci.
体内研究
(In Vivo)

Antitumor photosensitizer-10 (Compound NC) (0.7 mg/kg;瘤内注射;单次注射;注射后 1 小时给予 660 nm 光照射) 通过协同光动力疗法和铜死亡作用,在小鼠 4T1 乳腺癌模型中实现了 14 天内近乎完全的肿瘤生长抑制,且具有较高的体内生物安全性。

Animal Model: Balb/c mice (female, 5 weeks old, subcutaneously injected with 1 × 106 4T1 cells into the fourth mammary fat pad, tumors grown to ~100 mm3 before treatment)
Dosage: 0.7 mg/kg (no light); 0.7 mg/kg (with light irradiation)
Administration: intratumoral; single injection; 14 days observation period; 660 nm light irradiation at 100 mW cm-2 for 15 minutes (1 hour post-injection, light group only)
Result: Showed no appreciable tumor growth inhibition in the absence of light.
Almost completely suppressed tumor growth over the 14-day observation period, with relative tumor volume remaining near baseline when combined with light irradiation.
Induced the most pronounced tumor destruction, TUNEL-positive cell death, and DLAT aggregation (a marker of cuproptosis) in the light-treated group.
Caused no abnormal changes in mouse body weight, and H&E staining of major organs showed no marked physiological damage.

化学信息

分子量 738.23
分子式 C36H37Cl2CuN5O2S2+

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础